65 related articles for article (PubMed ID: 30206366)
1. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Blagden SP; Rizzuto I; Suppiah P; O'Shea D; Patel M; Spiers L; Sukumaran A; Bharwani N; Rockall A; Gabra H; El-Bahrawy M; Wasan H; Leonard R; Habib N; Ghazaly E
Br J Cancer; 2018 Oct; 119(7):815-822. PubMed ID: 30206366
[TBL] [Abstract][Full Text] [Related]
2. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P; Kazmi F; Aroldi F; Holmes T; Thompson D; Griffiths L; Qi C; Parkes M; Lord S; Veal GJ; Harrison DJ; Coyle VM; Graham J; Jeffry Evans TR; Blagden SP
J Exp Clin Cancer Res; 2024 Apr; 43(1):100. PubMed ID: 38566164
[TBL] [Abstract][Full Text] [Related]
3. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
Kapacee ZA; Knox JJ; Palmer D; Blagden SP; Lamarca A; Valle JW; McNamara MG
Med Oncol; 2020 Jun; 37(7):61. PubMed ID: 32529264
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
5. Comparative Pharmacology of a Bis-Pivaloyloxymethyl Phosphonate Prodrug Inhibitor of Enolase after Oral and Parenteral Administration.
Yan VC; Barekatain Y; Lin YH; Satani N; Hammoudi N; Arthur K; Georgiou DK; Jiang Y; Sun Y; Marszalek JR; Millward SW; Muller FL
ACS Pharmacol Transl Sci; 2023 Feb; 6(2):245-252. PubMed ID: 36798479
[TBL] [Abstract][Full Text] [Related]
6. Barriers and opportunities for gemcitabine in pancreatic cancer therapy.
Beutel AK; Halbrook CJ
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C540-C552. PubMed ID: 36571444
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent.
Serpi M; Ferrari V; McGuigan C; Ghazaly E; Pepper C
J Med Chem; 2022 Dec; 65(23):15789-15804. PubMed ID: 36417756
[TBL] [Abstract][Full Text] [Related]
8. Prodrugs of Nucleoside 5'-Monophosphate Analogues: Overview of the Recent Literature Concerning their Synthesis and Applications.
Roy B; Navarro V; Peyrottes S
Curr Med Chem; 2023; 30(11):1256-1303. PubMed ID: 36093825
[TBL] [Abstract][Full Text] [Related]
9. Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance.
Saiki Y; Hirota S; Horii A
Cancer Drug Resist; 2020; 3(4):819-831. PubMed ID: 35582220
[TBL] [Abstract][Full Text] [Related]
10. Phosphoryl Prodrugs: Characteristics to Improve Drug Development.
Kirby SA; Dowd CS
Med Chem Res; 2022 Feb; 31(2):207-216. PubMed ID: 35492863
[TBL] [Abstract][Full Text] [Related]
11. The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms
Schwenzer H; De Zan E; Elshani M; van Stiphout R; Kudsy M; Morris J; Ferrari V; Um IH; Chettle J; Kazmi F; Campo L; Easton A; Nijman S; Serpi M; Symeonides S; Plummer R; Harrison DJ; Bond G; Blagden SP
Clin Cancer Res; 2021 Dec; 27(23):6500-6513. PubMed ID: 34497073
[TBL] [Abstract][Full Text] [Related]
12. An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers.
Yu Y; Huang S; Chen J; Yu F; Zhang L; Xiang X; Deng J; Fang Z; Li J; Xiong J
Cancer Control; 2021; 28():10732748211017165. PubMed ID: 33982628
[TBL] [Abstract][Full Text] [Related]
13. In Reply.
McNamara MG; Valle JW
Oncologist; 2021 May; 26(5):e903-e904. PubMed ID: 33539624
[No Abstract] [Full Text] [Related]
14. Synthesis and Conformational Analysis of Fluorinated Uridine Analogues Provide Insight into a Neighbouring-Group Participation Mechanism.
Michailidou F; Lebl T; Slawin AMZ; Sharma SV; Brown MJB; Goss RJM
Molecules; 2020 Nov; 25(23):. PubMed ID: 33255573
[TBL] [Abstract][Full Text] [Related]
15. A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).
McNamara MG; Bridgewater J; Palmer DH; Faluyi O; Wasan H; Patel A; Ryder WD; Barber S; Gnanaranjan C; Ghazaly E; Evans TRJ; Valle JW
Oncologist; 2021 Apr; 26(4):e669-e678. PubMed ID: 33210382
[TBL] [Abstract][Full Text] [Related]
16. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer.
Randazzo O; Papini F; Mantini G; Gregori A; Parrino B; Liu DSK; Cascioferro S; Carbone D; Peters GJ; Frampton AE; Garajova I; Giovannetti E
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142664
[TBL] [Abstract][Full Text] [Related]
17. A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1.
Schwarz DMC; Williams SK; Dillenburg M; Wagner CR; Gestwicki JE
ACS Med Chem Lett; 2020 Sep; 11(9):1704-1710. PubMed ID: 32944137
[TBL] [Abstract][Full Text] [Related]
18. NUC-1031 in biliary tract cancer: from bench to bedside and back?
Boyd LNC; Peters GJ; Kazemier G; Giovannetti E
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1011-1014. PubMed ID: 32476108
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.
Arora M; Bogenberger JM; Abdelrahman A; Leiting JL; Chen X; Egan JB; Kasimsetty A; Lenkiewicz E; Malasi S; Uson PLS; Nagalo BM; Zhou Y; Salomao MA; Kosiorek HE; Braggio E; Barrett MT; Truty MJ; Borad MJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1063-1078. PubMed ID: 32440762
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
